Eugia Pharma gets USFDA nod for posaconazole injection, 300 mg/16.7 mL, single-dose vial
The approved product has an estimated market size of $25.4 million for the twelve months ending October 2023, according to IQVIA
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Candida infections
Lupin launches Posaconazole Delayed-Release Tablets
They are indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing…